InvestingPro’s fair value model captured ImmunityBio’s 45% downside
NegativeFinancial Markets

InvestingPro's fair value model has revealed a concerning 45% downside for ImmunityBio, indicating potential risks for investors. This significant drop highlights the challenges the company may face in the market, prompting investors to reassess their positions. Understanding these dynamics is crucial for making informed investment decisions.
— Curated by the World Pulse Now AI Editorial System